Mesa Laboratories, Inc. — Form 10-Q Summary
Reporting period: The supplied filing covers the three and nine months ended December 31, 2023, Mesa’s fiscal third quarter and first nine months of fiscal 2024. This differs from the request metadata identifying “2022 Q3.” Financial statements are unaudited and stated in thousands except per-share data.
Business Context
Mesa develops and manufactures life-sciences tools and quality-control products for pharmaceutical, healthcare, medical-device, laboratory, and related regulated markets. Its four reportable divisions are Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions.
Mesa completed the acquisition of GKE GmbH, SAL GmbH, and GKE China for approximately $88.8 million, net of cash and financial liabilities, during the quarter. GKE’s operating results were consolidated beginning October 16, 2023 for the German entities; GKE China’s results began consolidation on January 1, 2024.
Financial Performance and Metrics
| Metric | Three months ended Dec. 31, 2023 | Three months ended Dec. 31, 2022 | Nine months ended Dec. 31, 2023 | Nine months ended Dec. 31, 2022 |
|---|---|---|---|---|
| Revenue | $53.5 million | $54.3 million | $157.3 million | $163.5 million |
| Gross profit | $33.4 million | $32.8 million | $96.7 million | $100.5 million |
| Gross margin | 62.5% | 60.4% | 61.5% | 61.5% |
| Operating income | $(0.1) million | $3.4 million | $(0.8) million | $2.8 million |
| Net income | $2.1 million | $0.5 million | $0.3 million | $0.3 million |
| Diluted EPS | $0.39 | $0.08 | $0.06 | $0.06 |
| Operating cash flow | Not separately provided | Not separately provided | $31.3 million | $15.5 million |
Third-quarter net income benefited materially from $3.3 million of net unrealized foreign-currency gains, including gains related to a U.S.-dollar intercompany loan used to fund the GKE acquisition. The nine-month effective tax rate was unusually high at approximately 206.6% in the MD&A discussion, while the financial statement note reports 207.5%; the filing text does not clearly reconcile this discrepancy.
- Segment revenue: Sterilization and Disinfection Control increased 19% in the quarter and 9% year to date, including approximately $3.8 million of GKE revenue. Clinical Genomics declined 19% and 15%, respectively. Biopharmaceutical Development declined 19% and 18%. Calibration Solutions increased 13% and 9%.
- Segment margins: Consolidated gross margin was approximately 63% in the quarter and 62% year to date. Calibration Solutions improved to 59% in the quarter from 53%; Clinical Genomics declined to 51% from 52% in the quarter and to 50% from 55% year to date.
- Operating expenses: Quarterly operating expenses rose 14% to $33.5 million, primarily due to GKE-related expenses, including $0.8 million of acquisition and integration costs and $1.5 million of GKE operating expenses. Year-to-date operating expenses were essentially unchanged at $97.5 million.
- Non-cash charges: Nine-month amortization of acquisition-related intangibles was $22.4 million and stock-based compensation was $9.1 million.
Cash Flow, Liquidity, and Debt
- Cash and cash equivalents were $28.2 million at December 31, 2023, compared with $32.9 million at March 31, 2023.
- Working capital was $74.2 million, compared with $75.6 million at March 31, 2023.
- Nine-month cash flow was $31.3 million from operations, $(81.7) million from investing activities, and $45.8 million from financing activities. Investing cash use primarily reflected the $79.7 million cash portion of the GKE acquisition and $2.0 million of capital expenditures.
- The amended credit facility increased total commitments to $125 million and matures in March 2025. Mesa had $62.0 million outstanding at December 31, 2023, at an interest rate of approximately 7.2%; it repaid an additional $4.0 million in January 2024.
- Mesa had $172.5 million principal amount of 1.375% convertible senior notes outstanding, due August 15, 2025, with a net carrying value of $171.0 million. The notes were not convertible under the applicable conditions during the reported periods.
- Management stated that operating cash flow, available credit, and other potential financing sources are expected to meet ongoing operating needs, debt service, dividends, and anticipated capital expenditures. No shares have been sold under the company’s $150 million equity sale agreement.
Material Changes, Outlook, and Risks
- Revenue declined because of softer discretionary capital-equipment purchases, China’s economic slowdown and anti-corruption initiatives, and the prior loss of significant Clinical Genomics customer Sema4. GKE partially offset these pressures.
- Management expects macroeconomic challenges, including weak capital spending in life-sciences tools, China-related weakness, and high interest rates, to continue through at least the final quarter of fiscal 2024.
- Supply-chain disruptions and labor shortages that affected fiscal 2023 largely abated. Cost-containment actions included a Biopharmaceutical Development reduction in force and expense reductions following the Sema4 loss.
- Mesa is pursuing U.S. 510(k) clearance for certain GKE products, which management believes could expand GKE’s U.S. revenue opportunity; timing and outcome are uncertain.
- The GKE purchase-price allocation remains preliminary and could change materially, including allocations among goodwill, intangible assets, inventory, deferred taxes, and other assets and liabilities.
- Approximately $9.5 million of GKE consideration is held back for about 18 months as security against potential indemnification losses. Mesa also expects to pay additional Belyntic contingent consideration, including $0.6 million during the fourth quarter of fiscal 2024, with the remaining patents expected to result in payment within 12 months.
- Foreign-currency movements, high interest rates, product demand, supply-chain conditions, regulatory approvals, acquisitions and integration, cybersecurity, product liability, legal proceedings, tax matters, and international operations remain material risks.
- The company reported no material legal reserves and no impairment charges. Prior material weaknesses related to fair-value calculations and goodwill impairment assessments were reported as remediated, although GKE was excluded from the current internal-control assessment because it was recently acquired.
Important Facts for Investors to Verify
- Confirm the intended reporting period, because the supplied filing is for December 31, 2023 rather than 2022 Q3.
- Assess the sustainability of earnings excluding the $3.3 million foreign-currency gain and the effects of unusual tax-rate fluctuations.
- Monitor GKE integration, the final purchase-price allocation, U.S. 510(k) approvals, and the business’s contribution after full-period consolidation.
- Evaluate refinancing and liquidity needs ahead of the March 2025 credit-facility maturity and August 2025 convertible-note maturity.
- Track continued weakness in Clinical Genomics and Biopharmaceutical Development, particularly China demand, capital-equipment orders, and the effects of the Sema4 loss.
- Verify the company’s ability to maintain gross margins and operating cash flow while managing acquisition-related amortization, elevated interest expense, and macroeconomic pressure.